EGFR and breast cancer: Additionally, Chen et al. demonstrated that PRKG2 can inhibit the proliferation of various cancer cells, including lung, ovarian, and breast cancer cells, by blocking the MAPK/ERK, PI3K/Akt, Raf/MEK signaling pathways, and EGF/EGFR-related signaling cascades (49–52).